Mayo clinic tests personalized steroid dosing to tame pneumonia inflammation

NCT ID NCT05334316

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a personalized approach to giving the steroid dexamethasone to hospitalized adults with pneumonia. Instead of a standard dose, the amount is adjusted daily based on a blood marker called C-reactive protein (CRP). The goal is to reduce steroid side effects while still controlling inflammation. The trial will enroll 24 participants and compare this tailored strategy to usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dexamethasone

What this could lead to

If successful, this approach could reduce steroid side effects and improve recovery for pneumonia patients by giving the right dose at the right time.

What could go wrong

This is a small early-phase trial with only 24 participants, so results may not apply broadly. The personalized dosing strategy may not prove better than standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States